Xponance Inc. Has $890,000 Holdings in Natera, Inc. (NASDAQ:NTRA)

Xponance Inc. cut its position in Natera, Inc. (NASDAQ:NTRA) by 2.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,206 shares of the medical research company’s stock after selling 300 shares during the period. Xponance Inc.’s holdings in Natera were worth $890,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Oliver Lagore Vanvalin Investment Group raised its stake in shares of Natera by 109.3% in the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after acquiring an additional 389 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Natera by 15.7% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,844 shares of the medical research company’s stock worth $1,494,000 after acquiring an additional 3,228 shares during the last quarter. WCM Investment Management LLC raised its stake in shares of Natera by 101.2% in the fourth quarter. WCM Investment Management LLC now owns 145,996 shares of the medical research company’s stock worth $9,058,000 after acquiring an additional 73,419 shares during the last quarter. Cerity Partners LLC raised its stake in shares of Natera by 1,043.3% in the fourth quarter. Cerity Partners LLC now owns 90,423 shares of the medical research company’s stock worth $5,664,000 after acquiring an additional 82,514 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Natera by 28.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 720,160 shares of the medical research company’s stock worth $45,111,000 after acquiring an additional 159,993 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $91.28 on Friday. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $98.82. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37. The company has a 50 day moving average price of $87.29 and a two-hundred day moving average price of $67.00.

Natera (NASDAQ:NTRA) last issued its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The firm had revenue of $311.11 million during the quarter, compared to the consensus estimate of $300.38 million. As a group, analysts forecast that Natera, Inc. will post -2.35 EPS for the current year.

Insider Transactions at Natera

In other news, insider Jonathan Sheena sold 447 shares of the stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $90.22, for a total transaction of $40,328.34. Following the completion of the sale, the insider now owns 347,731 shares of the company’s stock, valued at $31,372,290.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Jonathan Sheena sold 447 shares of the stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $90.22, for a total transaction of $40,328.34. Following the completion of the sale, the insider now owns 347,731 shares of the company’s stock, valued at $31,372,290.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Daniel Rabinowitz sold 35,307 shares of the stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $75.09, for a total transaction of $2,651,202.63. Following the sale, the insider now directly owns 204,218 shares of the company’s stock, valued at approximately $15,334,729.62. The disclosure for this sale can be found here. Insiders sold 453,644 shares of company stock valued at $36,594,940 over the last quarter. Corporate insiders own 9.42% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price for the company in a research note on Friday, April 5th. Stephens reissued an “overweight” rating and set a $78.00 price target on shares of Natera in a research note on Tuesday, January 30th. Canaccord Genuity Group boosted their price target on shares of Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. Piper Sandler boosted their price target on shares of Natera from $70.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. Finally, BTIG Research boosted their price target on shares of Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a research note on Friday, December 29th. One investment analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $86.40.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.